==== Front FEBS Open Bio FEBS Open Bio 10.1002/(ISSN)2211-5463 FEB4 FEBS Open Bio 2211-5463 John Wiley and Sons Inc. Hoboken 36723270 10.1002/2211-5463.13568 FEB413568 FEBSOPEN-22-0925.R1 Kidney Metabolism Review Reviews Metabolic reprogramming heterogeneity in chronic kidney disease Metabolic reprogramming in chronic kidney disease V. Miguel and R. Kramann Miguel Verónica https://orcid.org/0000-0001-9863-0710 1 vmiguh00@gmail.com Kramann Rafael 1 1 Institute of Experimental Medicine and Systems Biology RWTH Aachen University Hospital Aachen Germany * Correspondence V. Miguel, Institute of Experimental Medicine and Systems Biology, RWTH Aachen University Hospital, Aachen, Germany Tel: +34680385016 E‐mail: vmiguh00@gmail.com 14 2 2023 7 2023 13 7 10.1002/feb4.v13.7 In the Limelight: FEBS Fellows 11541163 25 1 2023 16 12 2022 31 1 2023 © 2023 The Authors. FEBS Open Bio published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies. https://creativecommons.org/licenses/by/4.0/ This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. Fibrosis driven by excessive accumulation of extracellular matrix (ECM) is the hallmark of chronic kidney disease (CKD). Myofibroblasts, which are the cells responsible for ECM production, are activated by cross talk with injured proximal tubule and immune cells. Emerging evidence suggests that alterations in metabolism are not only a feature of but also play an influential role in the pathogenesis of renal fibrosis. The application of omics technologies to cell‐tracing animal models and follow‐up functional data suggest that cell‐type‐specific metabolic shifts have particular roles in the fibrogenic response. In this review, we cover the main metabolic reprogramming outcomes in renal fibrosis and provide a future perspective on the field of renal fibrometabolism. Chronic kidney injury drives cell‐type‐specific metabolic alterations with particular roles in fibrogenesis. Proximal tubular epithelial cells suffer mitochondrial damage and fatty acid oxidation impairment, triggering different cell death programs and cytokine release, attracting/activating immune cells and fibroblasts. Macrophage polarization also involves metabolic adjustments. Activated fibroblasts (myofibroblasts) are reprogrammed toward increased aerobic metabolism to acquire an extracellular matrix synthetic phenotype. fatty acid oxidation glycolysis kidney fibrosis mitochondria myofibroblasts tubular epithelial cells Federation of European Biochemical Societies 10.13039/100012623 source-schema-version-number2.0 cover-dateJuly 2023 details-of-publishers-convertorConverter:WILEY_ML3GV2_TO_JATSPMC version:6.3.0 mode:remove_FC converted:03.07.2023 ==== Body pmcAbbreviations CKD chronic kidney disease ECM extracellular matrix of proteins ESRD end‐ stage renal disease FA fatty acid FAO fatty acid oxidation FR‐PTC failed repair proximal tubule cell IL interleukin MPTP mitochondrial permeability transition pore OXPHOS oxidative phosphorylation PDGF platelet derived growth factor PT‐AcInj acute injury proximal tubule cell PTEC proximal tubular epithelial cell PT‐R repairing proximal tubule cell ROS reactive oxygen species TCA tricarboxylic acid TEC tubular epithelial cell TGF transforming growth factor TNF tumor necrosis factor Chronic kidney disease Chronic kidney disease (CKD) is a clinical condition that involves the progressive deterioration of renal function and represents an important medical, social, and economic burden with high morbidity and mortality rates. It affects about 10% of the worldwide population and is present in around 30–40% of patients with highly prevalent pathologies, such as hypertension and diabetes mellitus. CKD is predicted to be the 5th most important cause of death worldwide within the next 20 years [1]. Current CKD therapies are limited to immunosuppression in some fast‐progressive diseases or systemic blood pressure control. Although recent trials have reported promising results with SGLT2 inhibition, the majority of patients with CKD still progress toward end‐stage renal disease, which requires lifelong dialysis or kidney transplantation, creating an enormous unmet clinical need [2]. Regardless of etiology, progression of CKD includes the development of tubulointerstitial and glomerular fibrosis as a consequence of the excessive deposition of extracellular matrix proteins (ECM) along with persistent inflammation, tubular epithelial cell (TEC) dedifferentiation, and rarefaction of the peritubular microvasculature [3]. Myofibroblasts, derived from fibroblasts and PDGFRβ+/PDGFRα+ mesenchymal cells, are the principal ECM‐producing cells in the kidney [4]. Injury of the tubular epithelium occurs across most types of kidney disease at different stages and can, for instance, be caused by hypoxia, toxic compounds, or proteinuria with subsequent dedifferentiation of epithelial cells or even cell death. Sublethal damaged injured TECs may be drivers of fibrogenesis by releasing paracrine proinflammatory or profibrotic mediators [5]. Transforming growth factor‐β (TGF‐β) is the principal profibrogenic cytokine [6]. In addition, a variety of cytokines, such as interleukin 1 (IL‐1) and tumor necrosis factor (TNF), other key fibrogenic factors including platelet derived growth factor (PDGF), connective tissue growth factor, fibroblast growth factor 2, TNF‐like weak inducer of apoptosis (TWEAK) and Ang II [7], which involve the activation of TGF‐β, Notch, Wnt/β‐Catenin, PDGF, and Ang II/Reactive oxygen species (ROS)‐signaling pathways, are all considered crucial for kidney fibrosis development [8, 9, 10, 11, 12]. Experimental and clinical evidence obtained in the last few years have fostered a reinterpretation of the critical role of alterations in the main metabolic programs in the pathophysiology of renal fibrogenesis (Fig. 1A) [13]. They suggest that a cell‐type‐specific metabolic shift underlies the fibrogenic phenotype, whose understanding results essential to explore metabolism‐based effective therapeutic alternatives. Fig. 1 Renal metabolism within nephron tubular segments. (A) Major metabolic pathways in the kidney. Arrows with the same color link compounds from the same metabolic pathway. Forward arrows represent direct one‐step reactions, dashed arrows represent multistep reactions, and equilibrium arrows represent reversible reactions. (B) Examples of drugs targeting metabolic pathways. (C) Major metabolic pathways in each nephron tubular segment. The heat map indicates the approximate relative activation level of metabolic pathways within the tubular cells from each nephron segment. The scale bar ranges from yellow to black (high to low activation level). CD, collecting duct; DCT, distal convoluted tubule; DTL, descending limb of loop of Henle (LoH); S1, Segment 1; S2, Segment 2; S3, Segment 3; TAL, thick ascending limb of LoH. Metabolic alterations in renal fibrogenesis Infiltration of inflammatory cells, including lymphocytes, macrophages, dendritic cells, and mast cells, is a key feature of early stages of tubulointerstitial fibrosis [14]. The relationship between metabolism and immune cell function has gained momentum in recent years. Dramatic switches in cellular metabolism involve phenotypic and functional changes in macrophages. They are classically divided into two types: M1 and M2 according to their activation state and functions. The M1 proinflammatory polarization takes place during the early phase of renal injury and can be triggered by several stimuli including interferon gamma (IFN‐γ) and lipopolysaccharide in vitro. Macrophages acquire an M2 phenotype throughout the later stages of tissue repair in response to IL‐4, IL‐13, and IL‐1β and play important roles in wound healing and resolving inflammation. M1 macrophages are more dependent on glycolysis and present two breaks in the tricarboxylic acid (TCA) cycle, while M2 cells mainly rely on oxidative phosphorylation (OXPHOS; Fig. 2) [15]. Although a protective role for anti‐inflammatory M2 macrophages has been increasingly reported, their phenotypic plasticity and the conflicting macrophage phenotypes in vivo are major barriers for their therapeutic application [16]. Fig. 2 Cell‐type metabolic alterations in renal fibrogenesis. In CKD, PTECs undergo mitochondrial damage and impairment of FAO (their main energy source), triggering different cell death programs and the release of proinflammatory and profibrotic cytokines, attracting and activating immune cells and fibroblasts. M1 proinflammatory macrophage polarization mainly involves enhanced glycolysis and the blockage of the TCA cycle, while M2 macrophages, with important roles in wound healing and resolving inflammation, are more dependent on OXPHOS. Myofibroblasts are reprogrammed toward increased aerobic metabolism to acquire an ECM synthetic phenotype. Myofibroblasts also seem to undergo metabolic reprogramming characterized by increased aerobic glycolysis to meet the fast energy demand imposed by the ECM synthetic phenotype (Fig. 2) [17]. Beyond providing a rapid energy‐generating mechanism compared with OXPHOS, glycolysis produces by‐products such as lactate, which can affect other profibrotic pathways, such as TGF‐β signaling. It has been reported that chicken ovalbumin upstream promoter‐transcription factor II (COUP‐TFII), a transcription factor which directly regulates PGC‐1α expression, triggers a metabolic shift in human and mouse myofibroblast metabolism toward enhanced glycolysis and the generation of profibrotic mediators [18]. Inhibition of aerobic glycolysis has emerged as a potential antifibrotic strategy by reducing myofibroblast activation [19, 20, 21]. However, we still lack a complete understanding of stromal cellular heterogeneity. Different stromal subsets likely also differ in their metabolism in homeostasis and disease [22, 23]. In this review, we will focus on the region‐specific metabolic perturbations of proximal renal tubular cells, the better metabolically characterized cell type in renal fibrogenesis. Proximal renal tubular cells The kidney is the second organ in terms of mitochondrial content and oxygen consumption after the heart [24]. This is partially due to proximal tubules, which constitute ~ 50% of the total kidney cell number and require a high degree of active transport as they reabsorb 80% of the filtrate that traverses the glomerulus. Mitochondrial metabolism and particularly, fatty acid oxidation (FAO), is the preferred energy source, likely as an adaptation to generate large amounts of adenosine triphosphate (ATP), which also determines proximal tubular epithelial cell (PTEC) fate and function [25]. PTECs also rely on gluconeogenesis. Kidney is the only organ, aside from the liver, able to perform this metabolic program, contributing up to 20% of all glucose production (Fig. 1C) [26]. By contrast, podocytes, endothelial cells, and mesangial cells exhibit a lower degree of oxidative capacity also likely adapted to their function since their role requires less energy [27]. Therefore, distinct segments within the mature nephron utilize metabolic pathways likely adapted to their specific function. This feature is also conserved in the human nephron and has allowed to infer the susceptibility of each tubular segment toward ischemia [28]. Missing capability for anaerobic energy generation combined with its basal low pO2 suggests S3 segment of the proximal tubule as a primary site for hypoxia‐based injury [29]. FAO and oxidative phosphorylation Recent single‐cell RNA sequencing (scRNA‐seq) studies suggest considerable heterogeneity in PTEC states during fibrosis, including acute injury (PT‐AcInj), repairing (PT‐R), and failed repair proximal tubule cells (FR‐PTC), in addition to healthy S1/S2/S3 PTEC [30, 31]. Although FAO is transiently activated in PTECs (marked by Perilipin 2 (PLIN2) expression, a marker of intracellular lipid droplets) at the very early stages of ischemia–reperfusion injury and is associated with successful repair [32], its impairment has gained recognition as a potential pathogenic factor in the progression of kidney disease (Fig. 2). Defective amino acid transport and catalysis is also present in FR‐PTCs and is associated with CKD progression [33, 34]. Branched‐chain amino acids may provide TCA cycle intermediates in the absence of FAO [35]. Patients with CKD exhibit a drastic reduction of FAO and OXPHOS coupled with intracellular lipid deposition in the proximal tubular compartment, along with increased accumulation of short‐ and middle‐chain acyl‐carnitines, reflecting impaired FAO [36, 37, 38]. Several transcription factors, such as peroxisome proliferator‐activated receptor (PPAR)‐α, an important regulator of FAO genes, mitochondrial transcription factor A (TFAM), essential for mitochondrial encoded gene transcription and replication, as well as estrogen‐related receptor α (ESRRα) and PPARγ coactivator 1α (PGC1α), which regulate mitochondrial biogenesis, show decreased expression in patient samples and mouse models with CKD [39, 40]. Mechanistically, TGF‐β‐driven SMAD3 binding overlaps with the active enhancer histone tail modification H3K4me1 of the Ppargc1a promoter sequence, regulating the levels of proteins involved in fatty acid (FA) uptake and oxidation [39, 41]. Piret et al. [42] have proposed a novel transcriptional regulatory mechanism, involving a decrease in the expression of Krüppel‐like factor 15 (KLF15) in FAO loss. They have identified a close proximity in the binding sites of KLF15 and PPAR‐α in the promoters of the FAO genes Carnitine palmitoyl‐transferase 1 A (Cpt1a) and Acetyl‐CoA acyltransferase 2 (Acaa2). Post‐transcriptional targeting of Cpt1a by miR‐33, miR‐150, and miR‐495 has also been reported in human PTECs under a profibrotic insult in vitro [43, 44]. A prevailing line of evidence is that defects in energy production exert a negative impact beyond mere lipotoxicity. Although the inhibition of CD36‐, FATP2‐, or KIM‐1‐mediated FA uptake ameliorated experimental tubulointerstitial inflammation and fibrosis, enhanced lipid overload by tubular CD36 overexpression did not trigger spontaneous renal fibrogenesis in mice [39, 45, 46]. CPT1A is a FA mitochondrial shuttling enzyme, which catalyzes the FAO rate‐limiting step [47]. Both genetic deletion of Cpt1a and its pharmacological inhibition with etomoxir uncoupled mitochondrial function, aggravating tubular injury and interstitial fibrosis [39, 48]. Conversely, augmentation of FAO by CPT1A overexpression protected the tubule from injury [37]. The protective role of FAO restoration is also supported by indirect lines of evidence. Increased tubular expression of PGC‐1α and TFAM, and treatment with fenofibrate (a PPAR‐α agonist), C75 (a FA synthase blocker and CPT1A activator) or AICAR (an AMPK activator, which induces Cpt1a expression and reduces the levels of its physiological inhibitor, malonyl‐CoA) reduced experimental kidney fibrosis and associated functional impairment [39, 49, 50, 51]. The future development of specific, nontoxic CPT1 activators may pave the way to confirm this prospect. Under energy failure, ketones can be important substrates for the kidney. Lipolysis and FAO result in high levels of acetyl‐Co A that, when the oxidation capacity of the TCA cycle is exceeded, is instead diverted toward acetoacetate, which is subsequently reduced to β‐hydroxybutyrate. This process is called ketogenesis and occurs almost exclusively in liver mitochondria, but ketones can be reabsorbed by PTECs and be used for mitochondrial energy production and signaling purposes [52]. Physiological levels of ketones exert renoprotective effects based on their anti‐inflammatory and antioxidant properties. In fact, ketones are proposed to mediate the benefits of SGLT2 inhibitors in the kidney [53]. Alterations in mitochondrial dynamics and quality control also affect CKD development due to the cells´ failure to meet their energetic needs. Enhanced fragmentation of mitochondria has been observed in kidney tubules from CKD patients and mouse models. PTEC deletion of dynamin‐related protein (DRP1), the main regulator of mitochondrial fission, or its pharmacological inhibition with the drug Mdivi‐1, preserved mitochondrial structure and protected against renal fibrosis [54]. Conversely, PTEC deficiency of Mitofusin 2 (MFN2), which controls outer mitochondrial membrane fusion, accelerated kidney function recovery and enhanced survival after renal ischemia in mice [55]. Under the same type of injury, absence of OMA1 reduced the proteolysis of OPA1, which is involved in inner mitochondrial membrane fusion, ameliorating renal tubular damage [56]. Mitophagy selectively degrades damaged mitochondria via the autophagy machinery, which is triggered by the loss of mitochondrial membrane potential. Knockout mice for PINK1 or PARKIN genes, involved in mitophagosome formation, developed severe mitochondrial damage and kidney tubule cell death [57]. Conversely, enhancement of mitophagy has emerged as a strategy to improve mitochondrial health and provide protection against renal fibrosis. Thus, Bcl2‐interacting protein (BNIP)3 or BNIP3L (NIX), PINK1/PARKIN‐independent mitophagy receptors, ameliorate kidney damage [58, 59]. Damaged mitochondria release ROS and can lead to the cytosolic leakage of mitochondrial DNA (mtDNA), which activates cytosolic nucleotide sensors and induces inflammation. Pharmacological inhibition of the cytosolic DNA‐sensing cGAS–STING signaling pathway using C176, or genetic deletion of STING attenuates kidney tubule injury and fibrosis [51]. Knockout mice for AIM2, involved in another cytosolic nucleotide sensing pathway, showed reduced caspase‐1 activation and were protected from renal fibrosis and pyroptosis, a proinflammatory programmed cell death [60, 61]. Mitochondrial injury also triggers other cell death mechanisms including apoptosis, necroptosis, and ferroptosis, releasing proinflammatory cytokines which contribute to immune cell attraction or fibroblast activation. Apoptosis is a type of cell death, which occurs without the rupture of the cell membrane. The release of cytochrome c from the mitochondria through BAX/BAK pores promotes the oligomerization of a cytochrome c/Apaf‐1/caspase‐9 complex (apoptosome). It results in the activation of the initiator caspase‐9, which cleaves and activates downstream effector caspases‐3 and ‐7, leading to widespread substrate cleavage [62]. Attenuation of renal tubular cell apoptosis in BAX/BAK double KO mice prevented renal failure after ischemia [63]. Tumor necrosis factor‐alpha promotes necroptosis (programmed necrosis) by receptor‐interacting protein kinase‐3 (RIPK3)‐mediated NADPH oxidase‐4 (NOX4) recruitment to the mitochondria or through the mitochondrial permeability transition pore [64]. Ferroptosis is a caspase‐independent form of cell death characterized by iron‐dependent oxidative stress‐induced lipid peroxidation, leading to plasma membrane rupture, which underlies a TEC maladaptive repair [65, 66]. However, further research is needed to understand the relationship between different types of cell death and to address whether they determine an adaptive or maladaptive kidney repair response. Glucose and glutamine metabolism Proximal tubular epithelial cells also rely on gluconeogenesis to maintain glucose homeostasis by generating glucose from noncarbohydrate molecules. In the kidney, lactate is the principal substrate (50%) of gluconeogenesis, followed by glutamine (20%) and glycerol (10%). PTEC gluconeogenic function is impaired in CKD human biopsies and murine models and is associated with a worse renal prognosis (Fig. 2) [67]. Although PTECs produce and reabsorb glucose (mostly via SGLT2 on the apical membrane of S1‐2 segments and to a lesser extent via SGLT1 in the S3 segment), it is released into the circulation. With the exception of S3 segment, PTECs are almost unable to use glucose as energetic substrate. This is likely due to the closer localization of the S3 segments to the outer medulla and hence, to the limitation of O2 levels, compared with the S1 and S2 ones, which are restricted to the renal cortex. TECs in the more distal segments of the nephron exhibit enhanced glycolysis and progressively lose their capacity to carry out gluconeogenesis and OXPHOS (Fig. 1C). Under ischemic injury, PTECs are prompted to perform glycolysis instead of FAO, as reflected the accumulation of glycolysis intermediates and the upregulation of glycolytic enzymes [68]. Consistently, more lactate is present in FR‐PTs [69]. This is even maintained at late stages postreperfusion and in obstructive mouse models. Consistently, kidney metabolomics and RNA sequencing data from CKD patients also suggest enhanced glycolysis [70, 71, 72]. Of interest, glycolysis inhibition reduces tubular apoptosis but not its dedifferentiation, suggesting divergent effects [19]. Therefore, although this metabolic switch is initially cytoprotective, allowing PTECs to maintain energy production, its persistence may be maladaptive and is associated with worsen kidney prognosis. However, the exact cause of this metabolic switch during AKI and CKD transition remains unknown. Under low oxygen supply, HIF activation increases the expression of glucose transporters and catabolism genes, while inflammatory signals such as TGF‐β and IL‐β can contribute to the perpetuation of this metabolic perturbation by modulating co‐regulators of FAO and glycolysis such as hepatocyte nuclear factor 4 alpha (HNF4α) or ESRRA [73]. Glutamine supplies substrates to the TCA cycle via anaplerotic reactions mostly by producing α‐ketoglutarate (α‐KG). These reactions also generate ammonia, contributing to acid/base balance [74]. While glutamine is glutamate's main carbon source in all PT areas, glutamate oxidation in the TCA cycle differs between PTEC segments. Thus, there is a lower contribution of both glutamine and glutamate to the oxidative TCA cycle in S3 PTECs (Fig. 1C). Under ischemic injury, a reduction of glutamine‐derived oxidative TCA cycle metabolites was observed in FR‐PTs, although glutamine remained the main carbon source for glutamate in these cells (Fig. 2) [69]. Interestingly, even healthy PTECs within murine ischemic injury kidneys displayed this abnormal glutamate to TCA metabolism partitioning, both in the cortex and in the outer medulla, highlighting the relevance of TCA metabolite homeostasis to chronic kidney injury and repair. Chronic kidney disease has a profound impact on further metabolic routes [75]. Purine and polyamine metabolism is also altered in CKD. Thus, purine catabolism by‐products xanthine and uric acid are reduced both in human and mouse renal fibrotic tissue [76]. In turn, a higher level of serum uric acid, called hyperuricemia, is a risk factor of CKD [77]. Polyamines, essential for cell proliferation, are reduced in injured human PTECs. TGF‐β1 induces the degradation of ornithine decarboxylase, involved in polyamine biosynthesis, by targeting the Azin‐1/Antizyme1 pathway. Low levels of polyamines in turn activate and sustain the TGF‐β1‐induced profibrotic effects in an amplification loop [78]. The urea cycle, the primary metabolic pathway involved in the removal of ammonia (derived from amino acid breakdown) by its transformation into urea, is also impaired [79]. Conversely, several genes of the pentose phosphate pathway, which produces NADPH as reducing equivalents and pentoses as essential parts of nucleotides, showed increased expression in murine PTECs in vivo after renal ischemia [80]. Future perspectives In the last decade, the significance of metabolism in nephrology has gained widespread interest, resulting in a greater understanding of pathways with a role in renal disease. Bulk tissue metabolomic and transcriptomic platforms along with functional in vitro assays have allowed researchers to characterize the metabolic profile of CKD [38, 81]. Over the last few years, single‐cell/nuclei RNA sequencing has revolutionized the identification of cell types and states across kidney disease [4, 72]. Further, spatially resolved high‐resolution transcriptomic platforms along with improved deconvolution software pipelines continue to develop rapidly to provide a spatial cellular context within a tissue [82]. However, this technology does not provide a functional metabolic phenotype. While new approaches are emerging to decipher single‐cell metabolomics [83, 84], the activity of metabolic pathways cannot be determined only by measuring metabolite abundance. Recently, Wang et al. [69] followed a different strategy, performing 13C‐labeling fluxomic experiments ex vivo on cultured tissue slices, in combination with verified marker proteins and membrane lipid signatures, approaching a single‐cell (5 μm pixel size) resolution. This opens the door to measure metabolism with exceptional sensitivity and resolution by applying this technology to in vivo systematic analysis based on atom‐level metabolic network models, which have long been utilized for metabolic flux measurement in bulk material. All these observations suggest that a cell‐type‐specific metabolic shift could be a distinctive feature of new cell subpopulations with a differential role in adaptive or fibrotic kidney regeneration. Renal epithelial cells display shared and unique cell states and injury and repair responses across nephron segments in different CKD models [32]. In addition to their role in molecule production, metabolites are now known to regulate gene activity through DNA methylation and post‐translational histone changes [85]. Future research should focus on better analyzing mitochondrial malfunction and organelle interaction in disease since mitochondrial metabolism is a central hub in PTEC function and adaptation. Thus, development of noninvasive methods to monitor mitochondrial function in patients would also be useful. By contrast, the metabolic phenotype of other cell types involved in kidney injury and repair, such as myofibroblast and inflammatory cells, has been less studied. Cell‐type‐specific knockout models would help to clarify divergent effects derived from pharmacological metabolic inhibitors. Further, the impact of this metabolic reprogramming on surrounding cells, as well as the consequences of metabolite accumulation, is unknown. Since kidney fibrosis impacts nearly all renal cell types encompassing epithelia, stroma, endothelia and the immune system, it is desirable to construct a comprehensive network of cell–cell communications for translational studies. To explore this new avenue, more complex systems are needed, including integrated high‐resolution multiomics (metabolomic, transcriptomic, and fluxomic) analysis with spatial and temporal components, which will definitely unleash their full capacity as therapeutic targets. From a translational perspective, this new knowledge offers the potential of metabolism‐related drugs, which have been more deeply explored in the cancer field, to develop CKD therapeutic strategies (Fig. 1B) [86]. Further preclinical and, at some point, clinical studies are needed to target energy metabolism in fibrosis. Furthermore, determination of circulating metabolites as an innovative noninvasive methodology to identify and monitor the diagnosis, prognosis, and therapeutic response of CKD is also an impending application, albeit no definitive data have yet been moved to the clinic. Understanding the cell specificity of metabolite production in the kidney is essential to contextualize whole‐tissue metabolic changes, target validation and to improve the rational selection of biomarkers [87]. Therefore, elucidation of the relationship between metabolism and fibrosis will provide a new perspective on the identification of new cell subpopulations, uncover mechanisms of fibrogenesis, and open the possibility of exploring metabolism‐based effective therapeutic strategies. Conflict of interest The authors declare no conflict of interest. Acknowledgements VM is supported by a FEBS Long‐Term Fellowship. ==== Refs References 1 Kalantar‐Zadeh K , Jafar TH , Nitsch D , Neuen BL and Perkovic V (2021) Chronic kidney disease. Lancet 398 , 786–802.34175022 2 GBD Chronic Kidney Disease Collaboration (2020) Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 395 , 709–733.32061315 3 Djudjaj S and Boor P (2019) Cellular and molecular mechanisms of kidney fibrosis. Mol Aspects Med 65 , 16–36.29909119 4 Kuppe C , Ibrahim MM , Kranz J , Zhang X , Ziegler S , Perales‐Paton J , Jansen J , Reimer KC , Smith JR , Dobie R et al. (2021) Decoding myofibroblast origins in human kidney fibrosis. Nature 589 , 281–286.33176333 5 Yu SM and Bonventre JV (2020) Acute kidney injury and maladaptive tubular repair leading to renal fibrosis. Curr Opin Nephrol Hypertens 29 , 310–318.32205583 6 Huebener P and Schwabe RF (2013) Regulation of wound healing and organ fibrosis by toll‐like receptors. Biochim Biophys Acta 1832 , 1005–1017.23220258 7 Duffield JS (2014) Cellular and molecular mechanisms in kidney fibrosis. J Clin Invest 124 , 2299–2306.24892703 8 Meng XM , Tang PM , Li J and Lan HY (2015) TGF‐beta/Smad signaling in renal fibrosis. Front Physiol 6 , 82.25852569 9 Edeling M , Ragi G , Huang S , Pavenstadt H and Susztak K (2016) Developmental signalling pathways in renal fibrosis: the roles of notch, Wnt and Hedgehog. Nat Rev Nephrol 12 , 426–439.27140856 10 Ortiz A (2020) PDGFR‐beta and kidney fibrosis. EMBO Mol Med 12 , e11729.32072759 11 Laffer CL , Elijovich F , Sahinoz M , Pitzer A and Kirabo A (2020) New insights into the renin‐angiotensin system in chronic kidney disease. Circ Res 127 , 607–609.32790525 12 Irazabal MV and Torres VE (2020) Reactive oxygen species and redox signaling in chronic kidney disease. Cell 9 , 1342. 13 Zhu X , Jiang L , Long M , Wei X , Hou Y and Du Y (2021) Metabolic reprogramming and renal fibrosis. Front Med 8 , 746920. 14 Meng X‐M , Nikolic‐Paterson DJ and Lan HY (2014) Inflammatory processes in renal fibrosis. Nat Rev Nephrol 10 , 493–503.24981817 15 Wculek SK , Dunphy G , Heras‐Murillo I , Mastrangelo A and Sancho D (2022) Metabolism of tissue macrophages in homeostasis and pathology. Cell Mol Immunol 19 , 384–408.34876704 16 Wang X , Chen J , Xu J , Xie J , Harris DCH and Zheng G (2021) The role of macrophages in kidney fibrosis. Front Physiol 12 , 705838.34421643 17 Henderson NC , Rieder F and Wynn TA (2020) Fibrosis: from mechanisms to medicines. Nature 587 , 555–566.33239795 18 Li L , Galichon P , Xiao X , Figueroa‐Ramirez AC , Tamayo D , Lee JJ , Kalocsay M , Gonzalez‐Sanchez D , Chancay MS , McCracken KW et al. (2021) Orphan nuclear receptor COUP‐TFII enhances myofibroblast glycolysis leading to kidney fibrosis. EMBO Rep 22 , e51169.34031962 19 Wei Q , Su J , Dong G , Zhang M , Huo Y and Dong Z (2019) Glycolysis inhibitors suppress renal interstitial fibrosis via divergent effects on fibroblasts and tubular cells. Am J Physiol Renal Physiol 316 , F1162–F1172.30969803 20 Ding H , Jiang L , Xu J , Bai F , Zhou Y , Yuan Q , Luo J , Zen K and Yang J (2017) Inhibiting aerobic glycolysis suppresses renal interstitial fibroblast activation and renal fibrosis. Am J Physiol Renal Physiol 313 , F561–F575.28228400 21 Yu H , Zhu J , Chang L , Liang C , Li X and Wang W (2021) 3‐Bromopyruvate decreased kidney fibrosis and fibroblast activation by suppressing aerobic glycolysis in unilateral ureteral obstruction mice model. Life Sci 272 , 119206.33577854 22 Gibb AA , Lazaropoulos MP and Elrod JW (2020) Myofibroblasts and fibrosis: mitochondrial and metabolic control of cellular differentiation. Circ Res 127 , 427–447.32673537 23 Hewitson TD and Smith ER (2021) A metabolic reprogramming of glycolysis and glutamine metabolism is a requisite for renal Fibrogenesis‐why and how? Front Physiol 12 , 645857.33815149 24 O'Connor PM (2006) Renal oxygen delivery: matching delivery to metabolic demand. Clin Exp Pharmacol Physiol 33 , 961–967.17002675 25 Reidy KJ and Ross MJ (2021) Re‐energizing the kidney: targeting fatty acid metabolism protects against kidney fibrosis. Kidney Int 100 , 724–744. 26 Gerich JE , Meyer C , Woerle HJ and Stumvoll M (2001) Renal gluconeogenesis: its importance in human glucose homeostasis. Diabetes Care 24 , 382–391.11213896 27 Imasawa T and Rossignol R (2013) Podocyte energy metabolism and glomerular diseases. Int J Biochem Cell Biol 45 , 2109–2118.23806869 28 Hansen J , Sealfon R , Menon R , Eadon MT , Lake BB , Steck B , Anjani K , Parikh S , Sigdel TK , Zhang G et al. (2022) A reference tissue atlas for the human kidney. Sci Adv 8 , eabn4965.35675394 29 Scholz H , Boivin FJ , Schmidt‐Ott KM , Bachmann S , Eckardt KU , Scholl UI and Persson PB (2021) Kidney physiology and susceptibility to acute kidney injury: implications for renoprotection. Nat Rev Nephrol 17 , 335–349.33547418 30 Kirita Y , Wu H , Uchimura K , Wilson PC and Humphreys BD (2020) Cell profiling of mouse acute kidney injury reveals conserved cellular responses to injury. Proc Natl Acad Sci U S A 117 , 15874–15883.32571916 31 Muto Y , Wilson PC , Ledru N , Wu H , Dimke H , Waikar SS and Humphreys BD (2021) Single cell transcriptional and chromatin accessibility profiling redefine cellular heterogeneity in the adult human kidney. Nat Commun 12 , 2190.33850129 32 Li H , Dixon EE , Wu H and Humphreys BD (2022) Comprehensive single‐cell transcriptional profiling defines shared and unique epithelial injury responses during kidney fibrosis. Cell Metab 34 , 1977–1998.e9.36265491 33 Rabinowitz JD and Mutlu GM (2019) A metabolic strategy to reverse fibrosis? Nat Metab 1 , 12–13.32694811 34 Garibotto G , Sofia A , Saffioti S , Bonanni A , Mannucci I and Verzola D (2010) Amino acid and protein metabolism in the human kidney and in patients with chronic kidney disease. Clin Nutr 29 , 424–433.20207454 35 Piret SE , Guo Y , Attallah AA , Horne SJ , Zollman A , Owusu D , Henein J , Sidorenko VS , Revelo MP , Hato T et al. (2021) Kruppel‐like factor 6‐mediated loss of BCAA catabolism contributes to kidney injury in mice and humans. Proc Natl Acad Sci U S A 118 , e2024414118.34074766 36 Simon N and Hertig A (2015) Alteration of fatty acid oxidation in tubular epithelial cells: from acute kidney injury to renal fibrogenesis. Front Med 2 , 52. 37 Miguel V , Tituana J , Herrero JI , Herrero L , Serra D , Cuevas P , Barbas C , Puyol DR , Marquez‐Exposito L , Ruiz‐Ortega M et al. (2021) Renal tubule Cpt1a overexpression protects from kidney fibrosis by restoring mitochondrial homeostasis. J Clin Invest 131 , e140695.33465052 38 Afshinnia F , Rajendiran TM , Soni T , Byun J , Wernisch S , Sas KM , Hawkins J , Bellovich K , Gipson D , Michailidis G et al. (2018) Impaired beta‐oxidation and altered complex lipid fatty acid partitioning with advancing CKD. J Am Soc Nephrol 29 , 295–306.29021384 39 Kang HM , Ahn SH , Choi P , Ko YA , Han SH , Chinga F , Park AS , Tao J , Sharma K , Pullman J et al. (2015) Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development. Nat Med 21 , 37–46.25419705 40 Dhillon P , Park J , Hurtado Del Pozo C , Li L , Doke T , Huang S , Zhao J , Kang HM , Shrestra R , Balzer MS et al. (2021) The nuclear receptor ESRRA protects from kidney disease by coupling metabolism and differentiation. Cell Metab 33 , 379–394.e8.33301705 41 Zhou D and Liu Y (2016) Renal fibrosis in 2015: understanding the mechanisms of kidney fibrosis. Nat Rev Nephrol 12 , 68–70.26714578 42 Piret SE , Attallah AA , Gu X , Guo Y , Gujarati NA , Henein J , Zollman A , Hato T , Ma'ayan A , Revelo MP et al. (2021) Loss of proximal tubular transcription factor Kruppel‐like factor 15 exacerbates kidney injury through loss of fatty acid oxidation. Kidney Int 100 , 1250–1267.34634362 43 Price NL , Miguel V , Ding W , Singh AK , Malik S , Rotllan N , Moshnikova A , Toczek J , Zeiss C , Sadeghi MM et al. (2019) Genetic deficiency or pharmacological inhibition of miR‐33 protects from kidney fibrosis. JCI Insight 4 , e131102.31613798 44 Miguel V , Ramos R , Garcia‐Bermejo L , Rodriguez‐Puyol D and Lamas S (2021) The program of renal fibrogenesis is controlled by microRNAs regulating oxidative metabolism. Redox Biol 40 , 101851.33465566 45 Mori Y , Ajay AK , Chang JH , Mou S , Zhao H , Kishi S , Li J , Brooks CR , Xiao S , Woo HM et al. (2021) KIM‐1 mediates fatty acid uptake by renal tubular cells to promote progressive diabetic kidney disease. Cell Metab 33 , 1042–1061.e7.33951465 46 Chen Y , Yan Q , Lv M , Song K , Dai Y , Huang Y , Zhang L , Zhang C and Gao H (2020) Involvement of FATP2‐mediated tubular lipid metabolic reprogramming in renal fibrogenesis. Cell Death Dis 11 , 994.33219209 47 Schlaepfer IR and Joshi M (2020) CPT1A‐mediated fat oxidation, mechanisms, and therapeutic potential. Endocrinology 161 , bqz046.31900483 48 Yuan Q , Lv Y , Ding H , Ke Q , Shi C , Luo J , Jiang L , Yang J and Zhou Y (2021) CPT1alpha maintains phenotype of tubules via mitochondrial respiration during kidney injury and repair. Cell Death Dis 12 , 792.34392303 49 Han SH , Wu MY , Nam BY , Park JT , Yoo TH , Kang SW , Park J , Chinga F , Li SY and Susztak K (2017) PGC‐1alpha protects from notch‐induced kidney fibrosis development. J Am Soc Nephrol 28 , 3312–3322.28751525 50 Chen KH , Hsu HH , Lee CC , Yen TH , Ko YC , Yang CW and Hung CC (2014) The AMPK agonist AICAR inhibits TGF‐beta1 induced activation of kidney myofibroblasts. PLoS One 9 , e106554.25188319 51 Chung KW , Dhillon P , Huang S , Sheng X , Shrestha R , Qiu C , Kaufman BA , Park J , Pei L , Baur J et al. (2019) Mitochondrial damage and activation of the STING pathway Lead to renal inflammation and fibrosis. Cell Metab 30 , 784–799.e5.31474566 52 Rojas‐Morales P , Pedraza‐Chaverri J and Tapia E (2021) Ketone bodies for kidney injury and disease. Adv Redox Res 2 , 100009. 53 Perry RJ and Shulman GI (2020) Sodium‐glucose cotransporter‐2 inhibitors: understanding the mechanisms for therapeutic promise and persisting risks. J Biol Chem 295 , 14379–14390.32796035 54 Perry HM , Huang L , Wilson RJ , Bajwa A , Sesaki H , Yan Z , Rosin DL , Kashatus DF and Okusa MD (2018) Dynamin‐related protein 1 deficiency promotes recovery from AKI. J Am Soc Nephrol 29 , 194–206.29084809 55 Gall JM , Wang Z , Bonegio RG , Havasi A , Liesa M , Vemula P and Borkan SC (2015) Conditional knockout of proximal tubule mitofusin 2 accelerates recovery and improves survival after renal ischemia. J Am Soc Nephrol 26 , 1092–1102.25201884 56 Xiao X , Hu Y , Quiros PM , Wei Q , Lopez‐Otin C and Dong Z (2014) OMA1 mediates OPA1 proteolysis and mitochondrial fragmentation in experimental models of ischemic kidney injury. Am J Physiol Renal Physiol 306 , F1318–F1326.24671334 57 Li S , Lin Q , Shao X , Zhu X , Wu J , Wu B , Zhang M , Zhou W , Zhou Y , Jin H et al. (2020) Drp1‐regulated PARK2‐dependent mitophagy protects against renal fibrosis in unilateral ureteral obstruction. Free Radic Biol Med 152 , 632–649.31825802 58 Fu ZJ , Wang ZY , Xu L , Chen XH , Li XX , Liao WT , Ma HK , Jiang MD , Xu TT , Xu J et al. (2020) HIF‐1alpha‐BNIP3‐mediated mitophagy in tubular cells protects against renal ischemia/reperfusion injury. Redox Biol 36 , 101671.32829253 59 Zhang H , Bosch‐Marce M , Shimoda LA , Tan YS , Baek JH , Wesley JB , Gonzalez FJ and Semenza GL (2008) Mitochondrial autophagy is an HIF‐1‐dependent adaptive metabolic response to hypoxia. J Biol Chem 283 , 10892–10903.18281291 60 Komada T , Chung H , Lau A , Platnich JM , Beck PL , Benediktsson H , Duff HJ , Jenne CN and Muruve DA (2018) Macrophage uptake of necrotic cell DNA activates the AIM2 Inflammasome to regulate a Proinflammatory phenotype in CKD. J Am Soc Nephrol 29 , 1165–1181.29439156 61 Vilaysane A , Chun J , Seamone ME , Wang W , Chin R , Hirota S , Li Y , Clark SA , Tschopp J , Trpkov K et al. (2010) The NLRP3 inflammasome promotes renal inflammation and contributes to CKD. J Am Soc Nephrol 21 , 1732–1744.20688930 62 Jiang X and Wang X (2000) Cytochrome c promotes caspase‐9 activation by inducing nucleotide binding to Apaf‐1. J Biol Chem 275 , 31199–31203.10940292 63 Wei Q , Dong G , Chen JK , Ramesh G and Dong Z (2013) Bax and Bak have critical roles in ischemic acute kidney injury in global and proximal tubule‐specific knockout mouse models. Kidney Int 84 , 138–148.23466994 64 Sureshbabu A , Patino E , Ma KC , Laursen K , Finkelsztein EJ , Akchurin O , Muthukumar T , Ryter SW , Gudas L , Choi AMK et al. (2018) RIPK3 promotes sepsis‐induced acute kidney injury via mitochondrial dysfunction. JCI Insight 3 , e98411.29875323 65 Balzer MS , Doke T , Yang YW , Aldridge DL , Hu H , Mai H , Mukhi D , Ma Z , Shrestha R , Palmer MB et al. (2022) Single‐cell analysis highlights differences in druggable pathways underlying adaptive or fibrotic kidney regeneration. Nat Commun 13 , 4018.35821371 66 Tonnus W , Meyer C , Steinebach C , Belavgeni A , von Massenhausen A , Gonzalez NZ , Maremonti F , Gembardt F , Himmerkus N , Latk M et al. (2021) Dysfunction of the key ferroptosis‐surveilling systems hypersensitizes mice to tubular necrosis during acute kidney injury. Nat Commun 12 , 4402.34285231 67 Verissimo T , Faivre A , Rinaldi A , Lindenmeyer M , Delitsikou V , Veyrat‐Durebex C , Heckenmeyer C , Fernandez M , Berchtold L , Dalga D et al. (2022) Decreased renal gluconeogenesis is a Hallmark of chronic kidney disease. J Am Soc Nephrol 33 , 810–827.35273087 68 Lan R , Geng H , Singha PK , Saikumar P , Bottinger EP , Weinberg JM and Venkatachalam MA (2016) Mitochondrial pathology and glycolytic shift during proximal tubule atrophy after ischemic AKI. J Am Soc Nephrol 27 , 3356–3367.27000065 69 Wang G , Heijs B , Kostidis S , Mahfouz A , Rietjens RGJ , Bijkerk R , Koudijs A , van der Pluijm LAK , van den Berg CW , Dumas SJ et al. (2022) Analyzing cell‐type‐specific dynamics of metabolism in kidney repair. Nat Metab 4 , 1109–1118.36008550 70 Kwan B , Fuhrer T , Zhang J , Darshi M , Van Espen B , Montemayor D , de Boer IH , Dobre M , Hsu CY , Kelly TN et al. (2020) Metabolomic markers of kidney function decline in patients with diabetes: evidence from the chronic renal insufficiency cohort (CRIC) study. Am J Kidney Dis 76 , 511–520.32387023 71 Ahmadi A , Huda MN , Bennett BJ , Gamboa J , Zelnick LR , Smith LR , Chondronikola M , Raftery D , de Boer IH and Roshanravan B (2022) Chronic kidney disease is associated with attenuated plasma metabolome response to oral glucose tolerance testing. J Ren Nutr doi: 10.1053/j.jrn.2022.09.013 72 Park J , Shrestha R , Qiu C , Kondo A , Huang S , Werth M , Li M , Barasch J and Susztak K (2018) Single‐cell transcriptomics of the mouse kidney reveals potential cellular targets of kidney disease. Science 360 , 758–763.29622724 73 Quinn GZ , Dhillon P and Susztak K (2020) It takes two to tango: the role of dysregulated metabolism and inflammation in kidney disease development. Semin Nephrol 40 , 199–205.32303282 74 Yoo HC , Yu YC , Sung Y and Han JM (2020) Glutamine reliance in cell metabolism. Exp Mol Med 52 , 1496–1516.32943735 75 Zhao L , Dong M , Liao S , Du Y , Zhou Q , Zheng H , Chen M , Ji J and Gao H (2016) Identification of key metabolic changes in renal interstitial fibrosis rats using metabonomics and pharmacology. Sci Rep 6 , 27194.27256510 76 Kim IY , Lee DW , Lee SB and Kwak IS (2014) The role of uric acid in kidney fibrosis: experimental evidences for the causal relationship. Biomed Res Int 2014 , 638732.24877124 77 Dissanayake LV , Spires DR , Palygin O and Staruschenko A (2020) Effects of uric acid dysregulation on the kidney. Am J Physiol Renal Physiol 318 , F1252–F1257.32223309 78 Li R , Chung AC , Dong Y , Yang W , Zhong X and Lan HY (2013) The microRNA miR‐433 promotes renal fibrosis by amplifying the TGF‐beta/Smad3‐Azin1 pathway. Kidney Int 84 , 1129–1144.23868013 79 Vanholder R , Gryp T and Glorieux G (2018) Urea and chronic kidney disease: the comeback of the century? (in uraemia research). Nephrol Dial Transplant 33 , 4–12.28407121 80 Scantlebery AM , Tammaro A , Mills JD , Rampanelli E , Kors L , Teske GJ , Butter LM , Liebisch G , Schmitz G , Florquin S et al. (2021) The dysregulation of metabolic pathways and induction of the pentose phosphate pathway in renal ischaemia‐reperfusion injury. J Pathol 253 , 404–414.33338266 81 Beckerman P , Qiu C , Park J , Ledo N , Ko YA , Park AD , Han SY , Choi P , Palmer M and Susztak K (2017) Human kidney tubule‐specific gene expression based dissection of chronic kidney disease traits. EBioMedicine 24 , 267–276.28970079 82 Dixon EE , Wu H , Sulvaran‐Guel E , Guo J and Humphreys BD (2022) Spatially resolved transcriptomics and the kidney: many opportunities. Kidney Int 102 , 482–491.35788360 83 Rappez L , Stadler M , Triana S , Gathungu RM , Ovchinnikova K , Phapale P , Heikenwalder M and Alexandrov T (2021) SpaceM reveals metabolic states of single cells. Nat Methods 18 , 799–805.34226721 84 Minakshi P , Ghosh M , Kumar R , Patki HS , Saini HM , Ranjan K , Brar B and Prasad G (2019) Chapter 15 – Single‐cell metabolomics: technology and applications. In Single‐cell omics ( Barh D and Azevedo V , eds), pp. 319–353. Academic Press, Cambridge, MA. 85 Martinez‐Reyes I and Chandel NS (2020) Mitochondrial TCA cycle metabolites control physiology and disease. Nat Commun 11 , 102.31900386 86 Sainero‐Alcolado L , Liano‐Pons J , Ruiz‐Perez MV and Arsenian‐Henriksson M (2022) Targeting mitochondrial metabolism for precision medicine in cancer. Cell Death Differ 29 , 1304–1317.35831624 87 Cuevas‐Delgado P , Miguel V , Lamas S and Barbas C (2022) Chapter 6 – Metabolomics tools for biomarker discovery: applications in chronic kidney disease. In The Detection of Biomarkers ( Ozkan SA , Bakirhan NK and Mollarasouli F , eds), pp. 153–181. Academic Press, Cambridge, MA.